https://www.selleckchem.com/pr....oducts/act001-dmamcl
We similarly performed the explant assay on patient HNSCC tumors and found significant variability between the baseline environment of the tumors and their response to therapy. We propose that tumor explants provide a rapid biological assay to assess response to candidate immunotherapies that may allow matching therapies to individual patient tumors. Further development of explant approaches may allow screening and monitoring of treatment responses in HNSCC.Although serum tumor markers (STMs), clinicopathological characteristics a
Like
Comment
Share
